Multiple myeloma involving the cavernous sinus: a report of 3 cases and response to bortezomib.
Intracranial multiple myeloma is uncommon. Cavernous sinus involvement has rarely been reported, generally associated with treatment-refractory disease and poor outcome. We report clinical data and neuroradiologic findings of 3 patients with multiple myeloma and unilateral cavernous sinus involvement. At neuroradiology, this resulted from diffuse bone involvement as disease relapse (n=2) or focal dural disease (n=1) as the presenting sign. Interestingly, bortezomib treatment resulted in complete clinical resolution in 1 patient and partial clinical and significant magnetic resonance response in another, whereas in the literature, local radiation therapy has been reported as the only efficient treatment.
Gozzetti
Alessandro
A
Division of Hematology and Transplants, Policlinico Santa Maria alle Scotte, University of Siena, Italy. gozzetti@unisi.it
Cerase
Alfonso
A
Tarantino
Annachiara
A
Fabbri
Alberto
A
Bocchia
Monica
M
Pirrotta
Maria Teresa
MT
Lauria
Francesco
F
D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001897:Boronic Acids / Q000627:therapeutic use*; D000069286:Bortezomib; D002426:Cavernous Sinus / Q000473:pathology*; D017809:Fatal Outcome; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000175:diagnosis* / Q000188:drug therapy* / Q000473:pathology; D009367:Neoplasm Staging; D011719:Pyrazines / Q000627:therapeutic use*; D012008:Recurrence; D012680:Sensitivity and Specificity; D016896:Treatment Outcome
D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib